-
Posted: February 12th, 2019, 3:00pm GMT
Condition: Pancreatic Neoplasms
Interventions: Drug: Propranolol and etodolac; Other: Placebo
Sponsors: Assaf-Harofeh Medical Center; Sheba Medical Center
Not yet recruiting
-
Posted: January 14th, 2019, 3:00pm GMT
Condition: Colorectal Cancer
Interventions: Other: Erector spinae plane block; Other: Quadratus lumborum block; Drug: Propofol; Drug: Fentanyl NCS; Drug: Atracurium Injectable Product; Other: Endotracheal intubation; Drug: Anesthesia Maintenance; Drug: Muscle Relaxation
Sponsor: Mansoura University
Not yet recruiting
-
Posted: January 10th, 2019, 3:00pm GMT
Condition: Advanced Solid Tumors
Intervention: Drug: ASP1951
Sponsor: Astellas Pharma Global Development, Inc.
Recruiting
-
Posted: September 18th, 2018, 2:00pm GMT
Condition: Prostate Cancer
Intervention: Behavioral: High Intensity Interval Training bout
Sponsor: Rigshospitalet, Denmark
Recruiting
-
Posted: August 2nd, 2018, 2:00pm GMT
Condition: Adrenocortical Carcinoma
Intervention: Drug: Cabozantinib-s-malate
Sponsor: Wuerzburg University Hospital
Not yet recruiting
-
Posted: December 15th, 2017, 3:00pm GMT
Conditions: Adrenal Gland Neoplasm; Hypertension; Bone Diseases, Metabolic; Cardiovascular Disease; Hyperinsulinemia
Intervention:
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting
-
Posted: January 9th, 2017, 3:00pm GMT
Condition: Previously Untreated Acute Myeloid Leukemia
Interventions: Biological: Samalizumab (BAML-16-001-S1); Biological: BI 836858 (BAML-16-001-S2); Other: Laboratory Biomarker Analysis; Drug: Daunorubicin (BAML-16-001-S1); Drug: Cytarabine (BAML-16-001-S1); Drug: Azacitidine (BAML-16-001-S2); Drug: AG-221 (BAML-16-001-S3); Drug: Azacitidine (BAML-16-001-S3); Drug: Entospletinib (BAML-16-001-S4); Drug: Azacitidine (BAML-16-001-S4); Drug: Entospletinib (BAML-16-001-S5); Drug: Decitabine (BAML-16-001-S5); Drug: Entospletinib (BAML-16-001-S6); Drug: Azacitidine (BAML-16-001-S6); Drug: Daunorubicin (BAML-16-001-S6); Drug: Cytarabine (BAML-16-001-S6); Drug: Pevonedistat (BAML-16-001-S9); Drug: Azacitidine (BAML-16-001-S9); Drug: AG-120 (BAML-16-001-S16); Drug: Azacitidine (BAML-16-001-S16); Drug: Gilteritinib (BAML-16-001-S8); Drug: Decitabine (BAML-16-001-S8)
Sponsor: Beat AML, LLC
Recruiting
-
Posted: December 6th, 2016, 3:00pm GMT
Conditions: Solitary Pulmonary Nodule; Multiple Pulmonary Nodules
Intervention: Procedure: transbronchial biopsy
Sponsors: University of Pennsylvania; Andrew Haas; Anil Vachani; Anthony Lanfranco; Kevin Ma; Jeffrey Thompson; Edmund Moon
Recruiting
-
Posted: February 3rd, 2016, 3:00pm GMT
Condition: Adrenocortical Carcinoma
Intervention: Drug: Pembrolizumab
Sponsors: Memorial Sloan Kettering Cancer Center; Merck Sharp & Dohme Corp.
Recruiting
-
Posted: June 2nd, 2015, 2:00pm GMT
Condition: Neoplasms
Intervention: Behavioral: Exercise for Cancer Patients
Sponsor: University of Rochester
Recruiting
-
Posted: November 2nd, 2009, 3:00pm GMT
Conditions: Endocrine Tumors; Thyroid Neoplasms; Parathyroid Neoplasms; Adrenal Neoplasm; Neuroblastoma
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting
-
Posted: June 29th, 2000, 2:00pm GMT
Condition: Adrenal Gland Neoplasm
Intervention:
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting